Benzodiazepines, Urine, Quantitative
Ordering Recommendation
Preferred test to follow-up presumptive results. For general screening, Benzodiazepines Urine Screen with Reflex to Quantitation (2012225) is preferred.
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
New York DOH Approval Status
Specimen Required
Random urine.
Transfer 0.5 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Room temperature.
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years
Reference Interval
Drugs Covered | Cutoff Concentrations |
Alprazolam | 5 ng/mL |
Alpha-hydroxyalprazolam | 5 ng/mL |
Chlordiazepoxide | 20 ng/mL |
Clonazepam | 5 ng/mL |
7-aminoclonazepam | 5 ng/mL |
Diazepam | 20 ng/mL |
Lorazepam | 20 ng/mL |
Midazolam | 20 ng/mL |
Alpha-hydroxymidazolam | 20 ng/mL |
Nordiazepam | 20 ng/mL |
Oxazepam | 20 ng/mL |
Temazepam | 20 ng/mL |
Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Drugs covered: alprazolam, alpha-hydroxyalprazolam, chlordiazepoxide, clonazepam, 7-aminoclonazepam, diazepam, lorazepam, midazolam, alpha-hydroxymidazolam, nordiazepam, oxazepam and temazepam..
Positive cutoff: 20 ng/mL unless specified below:
Alprazolam 5 ng/mL
Alpha-hydroxyalprazolam 5 ng/mL
Clonazepam 5 ng/mL
7-aminoclonazepam 5 ng/mL
For medical purposes only; not valid for forensic use.
Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescription drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
Compare to Pain Management, Benzodiazepines, Quantitative, w/ medMATCH, Urine (Drugs of Abuse Confirmation/Quantitation - Benzodiazepines - Urine); Pain Management, Benzodiazepines, w/Confirmation w/med MATACH, Urine (Drugs of Abuse Confirmation/Quantitation - Benzodiazepines - Urine).
Hotline History
CPT Codes
80346 (Alt code: G0480)
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2007834 | Diazepam, Urn, Quant | 16227-1 |
2007835 | Oxazepam, Urn, Quant | 16201-6 |
2007836 | Temazepam, Urn, Quant | 20559-1 |
2007837 | Nordiazepam, Urn, Quant | 16228-9 |
2007838 | Lorazepam, Urn, Quant | 17088-6 |
2007839 | Alprazolam, Urn, Quant | 59615-5 |
2007840 | Alpha-hydroxyalprazolam, Urn, Quant | 16348-5 |
2007841 | Clonazepam, Urn, Quant | 16229-7 |
2007842 | 7-aminoclonazepam, Urn, Quant | 51776-3 |
2007846 | Midazolam, Urn, Quant | 16233-9 |
2007847 | Chlordiazepoxide, Urn, Quant | 20522-9 |
2008511 | Alpha-hydroxymidazolam, Urn, Quant | 59590-0 |